Adult-onset temporal lobe epilepsy suspicious for autoimmune pathogenesis: Autoantibody prevalence and clinical correlates.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
07
2020
accepted:
13
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Temporal lobe adult-onset seizures (TAOS) related to autoimmunity represent an increasingly recognized disease syndrome within the spectrum of epilepsies. In this context, certain autoantibodies (autoABs) were often associated with limbic encephalitis (LE). Here, we aimed to gain insights into (a) the distribution of 'neurological' autoABs (neuroABs, defined as autoABs targeting neuronal surface structures or 'onconeuronal' ABs or anti-glutamate acid decarboxylase 65 (GAD65) autoABs) in a large consecutive TAOS patient cohort, to characterize (b) clinical profiles of seropositive versus seronegative individuals and to find (c) potential evidence for other autoABs. Blood sera/cerebrospinal fluid (CSF) of TAOS patients (n = 800) and healthy donors (n = 27) were analyzed for neuroABs and screened for other autoABs by indirect immunofluorescence on hippocampal/cerebellar sections and immunoblots of whole brain and synaptosome lysates. Serological results were correlated with clinico-neuropsychological features. 13% of TAOS patients (n = 105) were neuroAB+, with anti-GAD65 and anti-N-methyl-D-aspartate receptors (NMDAR) as most frequent autoABs in this group. In our screening tests 25% of neuroAB- patients (n = 199) were positive (screening+), whereas all control samples were negative (n = 27). Intriguingly, key clinico-neuropsychological characteristics including magnetic resonance imaging (MRI) findings, epileptiform electroencephalographic (EEG) activity, and inflammatory cellular infiltrates in CSF were shared to a greater extent by neuroAB+ with neuroAB-/screening+ patients than with neuroAB-/screening- patients. Serological testing in a large consecutive TAOS patient series revealed seropositivity for anti-GAD65 autoABs as the most frequent neuroAB. Intriguingly, neuroAB+ individuals were virtually indistinguishable from neuroAB-/screening+ patients in several major clinical features. In contrast, neuroAB-/screening- TAOS patients differed in many parameters. These data support the potential presence of so far unrecognized autoABs in patients with TAOS.
Identifiants
pubmed: 33119692
doi: 10.1371/journal.pone.0241289
pii: PONE-D-20-21286
pmc: PMC7595292
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241289Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neurology. 2007 Sep 18;69(12):1236-44
pubmed: 17875912
JAMA Neurol. 2017 Apr 1;74(4):397-402
pubmed: 28166327
J Neuroimmunol. 2002 Jan;122(1-2):100-5
pubmed: 11777548
Front Cell Neurosci. 2016 May 18;10:130
pubmed: 27242441
Epilepsy Behav. 2018 May;82:25-28
pubmed: 29579551
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1145-1153
pubmed: 32859745
Epilepsia. 2013 Jun;54(6):1028-35
pubmed: 23464826
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40
pubmed: 15258215
Eur J Neurol. 2018 May;25(5):e59-e60
pubmed: 29667352
Epilepsia. 2017 Sep;58(9):1542-1550
pubmed: 28681401
Brain. 2000 Jul;123 ( Pt 7):1481-94
pubmed: 10869059
Neurology. 1995 Oct;45(10):1873-8
pubmed: 7477985
J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):379-85
pubmed: 25855399
J Neuroimmunol. 2016 Mar 15;292:108-15
pubmed: 26943968
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):894-9
pubmed: 19357127
Ann Neurol. 2011 May;69(5):892-900
pubmed: 21416487
Brain. 2008 Oct;131(Pt 10):2553-63
pubmed: 18687732
J Clin Anesth. 2013 Sep;25(6):491-5
pubmed: 23965208
Front Neurol. 2015 Aug 28;6:189
pubmed: 26379623
Lancet Neurol. 2011 Aug;10(8):759-72
pubmed: 21777830
Epilepsia. 2020 Jul;61(7):1341-1351
pubmed: 32544279
Ann Neurol. 1999 Feb;45(2):162-7
pubmed: 9989617
Curr Neurol Neurosci Rep. 2011 Jun;11(3):298-304
pubmed: 21331529
Ann Neurol. 2020 Jun;87(6):869-884
pubmed: 32196746
Curr Opin Neurol. 2011 Apr;24(2):146-53
pubmed: 21358545
Ann Neurol. 2013 Jan;73(1):120-8
pubmed: 23225603
Eur J Neurol. 2018 Aug;25(8):1011-1016
pubmed: 29667271
Brain. 2004 Aug;127(Pt 8):1822-30
pubmed: 15201193
Epilepsia. 2017 Apr;58(4):522-530
pubmed: 28276060
Epilepsia. 2011 May;52 Suppl 3:12-7
pubmed: 21542840
Epilepsia. 2011 May;52 Suppl 3:18-22
pubmed: 21542841
Epilepsia. 2010 May;51(5):760-7
pubmed: 19817821
Lancet Neurol. 2010 Jan;9(1):67-76
pubmed: 19962348
Neurology. 2000 Dec 26;55(12):1823-8
pubmed: 11134380
Epilepsy Res. 2011 Nov;97(1-2):146-56
pubmed: 21873031
Clin Cancer Res. 1998 Nov;4(11):2819-24
pubmed: 9829748
Ann N Y Acad Sci. 2015 Mar;1338:94-114
pubmed: 25315420
Ann Neurol. 2001 Sep;50(3):339-48
pubmed: 11558790
JAMA Neurol. 2014 May;71(5):569-74
pubmed: 24687183
Neuroradiology. 2006 Jun;48(6):380-6
pubmed: 16586118
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Brain. 2004 Mar;127(Pt 3):701-12
pubmed: 14960497
Handb Clin Neurol. 2016;133:107-20
pubmed: 27112674
Ann Neurol. 2010 Apr;67(4):470-8
pubmed: 20437582
N Engl J Med. 2017 Oct 26;377(17):1648-1656
pubmed: 29069555
Neurology. 1998 Oct;51(4):1146-50
pubmed: 9781545
Nat Med. 1998 Nov;4(11):1321-4
pubmed: 9809559
Clin Neurol Neurosurg. 1995 Feb;97(1):95-100
pubmed: 7788981
Ophthalmologica. 2012;228(3):131-42
pubmed: 22846442
Lancet Neurol. 2014 Feb;13(2):167-77
pubmed: 24360484